The SMN1 gene provides instructions for a protein that keeps nerve cells controlling muscles working normally. This gene plays an important role in keeping motor neurons healthy so movements like lifting a cup or holding your head up stay strong. If SMN1 does not work due to missing or harmful copies, a child can develop spinal muscular atrophy, with progressive muscle weakness and sometimes trouble breathing or swallowing. Many people have two working copies, and testing often looks for deletions or copy number changes that run in families.
What is a gene?
Genes are stretches of DNA that carry instructions your cells use to make molecules or manage activities in the body. Some genes provide the directions for building proteins, which act as the cell’s main working components. Others are used mostly to regulate when certain processes happen, where they take place, and how strongly they occur. As a group, genes affect how your body grows and works, and they can also influence how you react to food, stress, or medications. For a deeper look at this topic, you can find more information in the LearnHub.
Overview
SMN1Gene function
What if the gene works
The SMN1 gene makes SMN protein, which helps cells assemble key tools for processing RNA. Adequate SMN supports survival of motor neurons, helping maintain muscle control and normal movement.
Risk
What if the gene does not work
When the SMN1 gene isn’t working, motor nerve cells can fail, causing spinal muscular atrophy with muscle weakness and wasting, sometimes breathing or swallowing problems; DNA changes range from mild to severe, shaping symptom timing and severity.
Treatment
What does that mean for your treatment
SMN1 gene results help select spinal muscular atrophy treatments that restore survival motor neuron protein. The SMN2 gene partly compensates, and nusinersen or risdiplam can increase SMN2 output. Gene replacement therapy, onasemnogene abeparvovec, may also be used.
Conditions associated with SMN1
Gene function
What if the gene works
Smooth, coordinated movement depends on nerve cells that can keep up with constant day-to-day demands. Across many tissues, the SMN1 gene contributes to steady, routine cell activity by helping cells handle their genetic instructions. This SMN1 gene function is especially important in motor neurons, which need reliable “message processing” to support muscle control.
The SMN1 gene helps your cells prepare RNA messages so they can be read correctly to make proteins. It supports the cell’s splicing system (a normal editing step that trims and joins RNA before it is used).
Inside your cells, the SMN1 gene helps build key parts used for RNA editing and handling. Its protein helps assemble small RNA protein units that your cells reuse many times during everyday protein production.
What is a variant?
A genetic variant is a minor difference in a gene’s DNA sequence. These differences are widespread and help shape typical human variation, such as traits related to appearance, metabolism, or the way the body reacts to environmental factors. Many variants do not cause any obvious changes and are part of normal genetic diversity. In certain situations, though, a variant can more strongly affect how a gene works and may play a role in, or directly cause, a genetic condition.
Genetic variants
What if the gene does not work
Changes in the SMN1 gene can reduce or stop a protein needed by the nerves that control muscles, leading to spinal muscular atrophy (SMA). Some people have severe mutations, such as a missing SMN1 copy, while others carry milder variants that leave some activity. This range can affect symptoms, how early weakness starts, and how much movement is affected, often influenced by SMN2 copy number. People learn about this through SMN1 gene mutation and spinal muscular atrophy testing.
How variants are linked to conditions
Certain inherited changes in SMN1 can cause spinal muscular atrophy (SMA), a condition marked by progressive muscle weakness. In most cases, the diagnosis is confirmed when both copies of SMN1 are missing or not working. People with one nonworking copy are usually healthy carriers, but the result matters for family planning. This SMN1 gene variants and spinal muscular atrophy link is well established across populations, with disease severity varying widely between individuals.
A variant is not necessarily a diagnosis
Human genetics naturally includes many genetic variants, and these differences are widespread across the general population. In most cases, variants do not directly affect health and instead reflect ordinary human diversity. With many genes, a variant that has been linked to a condition points to a potential association rather than a certain diagnosis, particularly when risk is shaped by multiple genes along with environmental factors. Still, there are situations where one well-understood variant in a particular gene is enough to confirm a diagnosis.
Are there things that can increase or change my risk?
For spinal muscular atrophy linked to SMN1, the chance of being affected is mostly set by the SMN1 changes a baby is born with, so lifestyle and diet do not meaningfully change it. What can change is the chance of having an affected child: it is higher when both biological parents carry an SMN1 change or there is a family history. Severity can also vary between babies, partly due to other genes such as SMN2.
Inheritance of SMN1 variants
Most people with spinal muscular atrophy inherit two nonworking copies of the SMN1 gene, one from each parent. This SMN1 gene inheritance pattern is autosomal recessive, so parents are often healthy carriers, and when both are carriers each pregnancy has a 25% chance of an affected child, a 50% chance of a carrier child, and a 25% chance of a child with two working copies. Carriers and affected individuals can be born to any sex, and the gene change can be passed on by either parent.
What does my SMN1 result mean for my family?
Seek medical advice if an SMN1 result raises concerns about spinal muscular atrophy in your family, especially during pregnancy planning, a current pregnancy, or if a baby has weak muscle tone, trouble feeding, or breathing problems. A genetics professional can explain who in the family may also be affected or be carriers, and what that could mean for future children. Get urgent care right away for any breathing difficulty or severe weakness.
Genetic information
Genetic testing
How you find out about variants
SMN1 genetic testing can show whether you carry a change linked to spinal muscular atrophy (SMA) or whether an affected person has an SMN1-related diagnosis. Testing usually uses a blood or saliva sample, and the lab measures SMN1 copy number and may also look for smaller DNA changes. Results help clarify carrier status or diagnosis, but they do not predict how symptoms will progress.
When should I consider getting a genetic test?
Consider SMN1 genetic testing if you or your partner has a family history of spinal muscular atrophy (SMA), a condition that can cause severe muscle weakness. It can also be helpful when planning a pregnancy, including routine carrier screening, to learn whether both parents carry an SMN1 change. Testing is often considered if a baby or child has low muscle tone, trouble moving, or if newborn or prenatal screening suggests SMA.
A genetic result is only one part of your health story
Genetic test results can be very informative, but what they can tell you varies with the condition and with the specific kind of variant found. Your health over time is also shaped by factors like lifestyle, environment, age, and your medical history. With some conditions, particularly those affected by many genes, genetic findings provide helpful background rather than a definite prediction and make the most sense when considered together with the rest of your care. In other situations, a genetic result can be more straightforward and offer a clear conclusion. When it comes to how someone responds to medications, genetic information can also help put personal experiences into context.
Pharmacogenetics
How variants shape your response to medicine
Genetic variation can affect how people respond to medicines, and for spinal muscular atrophy, results involving the SMN1 gene are part of that bigger picture. If you have a condition caused by changes in the SMN1 gene, related genetic factors such as the number of copies of the SMN2 gene can influence the typical severity of symptoms and may be linked to how much benefit someone gets from treatments that support SMN protein levels. More broadly, small DNA differences can change how the body handles a drug or how sensitive target tissues are to it, so the same medication can feel more effective for one person and less so for another. Genetics is only one factor, and age, overall health, and other medicines you take can also shape treatment response.
What is Pharmacogenetics?
Pharmacogenetics is a branch of science focused on how differences in your genes can affect the way medications work. By examining relationships between specific genes and specific drugs, it helps explain why the same treatment may not have the same effect in everyone. For many medicines, genetic factors can influence how much effect a drug has or how your body handles it. This information can support treatment choices that are better informed and more tailored to the individual. More details on this subject are available in the LearnHub.
Drugs influenced by the SMN1 gene
When should I seek medical advice?
Seek medical advice if you or your child has muscle weakness, low muscle tone, trouble swallowing, or breathing problems, especially with delayed sitting, standing, or walking. Contact your care team right away if someone with an SMN1-related condition gets weaker, has frequent chest infections, or new feeding issues. Share SMN1 results with your clinicians since they can affect treatment options.
History
Spinal muscular atrophy was recognized for generations as an inherited condition that could affect babies, children, or adults, but the genetic cause was unclear for a long time. In the mid-1990s, researchers linked most cases to changes in the SMN1 gene, a breakthrough that made precise genetic diagnosis and carrier testing possible. Building on this early work, scientists clarified why some families had milder or later-onset symptoms, which helped guide prognosis and research. In the 2000s and 2010s, genetic testing became more widely available and began to shape earlier identification, including through newborn screening programs in some regions. Starting in 2016, the first disease-modifying treatments for spinal muscular atrophy reached clinical care, marking a major shift from supportive care alone to targeted therapy.